Real world impact of prescription eye drop therapy adherence on visual field progression among Ontario patients with open-angle glaucoma
Client: IQVIA Solutions Canada Inc.
Project ID: P2022-112 / 2023 0970 332 000
Research Question/Objectives: The client has several objectives around the treatment of intraocular pressure (IOP).
- the proportion of patients in monotherapy, dual therapy or multiple agents at index, 12-, 24-, 36-, 60-, 84-, and 120-months post-index.
- the average duration of IOP-lowering prescription eye drop use prior to the occurrence of a non-eye drop intervention for POAG, initiation of an oral IOP-lowering medication or treatment discontinuation for patient on IOP-lowering prescription eye drops for at least 5 years
- the rate of switching and treatment escalation following the initiation of the index IOP-lowering prescription eye drop therapy.
- the rate of discontinuation of IOP-lowering prescription eye drops by class and combination of classes of medication for patients on IOP-lowering prescription eye drops for at least 5 years
- patient adherence to index treatment overall and for each class and combination of classes of IOP-lowering prescription eye drops medication at 3-, 6-, 12- and 24-months post-index for patients on IOP-lowering prescription eye drops for at least 5 years.
- healthcare resource utilization (HCRU) including, but not limited to, physician and hospital visits for eye care of patients using IOP-lowering prescription eye drops overall, by class and combination of classes of medication.
- time to and type of eye procedures for PAG diagnosis for patients on IOP-lowering prescription eye drops for at least 5 years
Availability of Results: September 2024